IPP Bureau
Cube Biotech acquires IBA Lifesciences
By IPP Bureau - January 14, 2025
The combined entity will leverage its complementary strengths to deliver unparalleled solutions in protein purification and stabilization
Pfizer’s Sasanlimab in combination with BCG improves survival in patients with bladder cancer
By IPP Bureau - January 13, 2025
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
Senores receives ANDA approval for marketing Metoprolol Tartrate and Hydrochlorothiazide Tablet USP
By IPP Bureau - January 13, 2025
Metoprolol Tartrate and Hydrochlorothiazide Tablet is the combination tablet of metoprolol tartrate, a beta adrenoceptor blocker and hydrochlorothiazide (HCTZ), a thiazide diuretic, indicated for the treatment of hypertension, to lower blood pressure
Apotex acquires US rights to PROVIGIL and NUVIGIL
By IPP Bureau - January 13, 2025
PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy
Steven R. Smith joins Zealand Pharma as Senior Global Medical Advisor in Obesity
By IPP Bureau - January 13, 2025
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
USFDA classifies Biocon Biologics Johor Bahru site, Malaysia as VAI
By IPP Bureau - January 13, 2025
Biocon Biologics remains committed to global standards of quality and compliance
Zaynich achieves over 97% efficacy in clinical study for meropenem-resistant gram-negative pathogens
By IPP Bureau - January 13, 2025
The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
Iconovo and Lonza to collaborate on formulation development of an intranasal biologic
By IPP Bureau - January 13, 2025
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
Aragen secures $100 million investment from Quadria Capital
By IPP Bureau - January 13, 2025
Investment will fund expansion to meet rising demand for CRDMO services
Genome India Project marks a defining moment for country's biotechnology landscape: Modi
By IPP Bureau - January 11, 2025
Modi remarked that more than 20 illustrious research institutions such as IISc, IITs, CSIR and DBT-BRIC have played a major role in this research
Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies
By IPP Bureau - January 10, 2025
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
Synaffix and Mitsubishi Tanabe Pharma ink license agreement for ADC technology
By IPP Bureau - January 10, 2025
Usage of Synaffix GlycoConnect, HydraSpace and toxSYN ADC technologies to enhance efficacy, tolerability and target engagement
Merieux completes acquisition of Bureau Veritas' food testing activities in Canada and US
By IPP Bureau - January 10, 2025
The transaction is part of a broader agreement with Bureau Veritas covering its worldwide food laboratory testing activities
ZIM Laboratories and Neuraxpharm granted marketing authorization for Buprenorphine Sublingual Film in Europe
By IPP Bureau - January 10, 2025
According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually
Windlas Biotech’s new injectable facility receives GMP certification
By IPP Bureau - January 10, 2025
The certification marks a new chapter in Windlas Biotech’s growth trajectory,
